Further research is required to validate these findings and to explore the potential for therapies targeting DNA methylation (i.e. by microRNAs) that can potentially modulate PRDM16 expression or its regulatory mechanisms in AML. This evidence concerns the gene PRDM16 and acute myeloid leukemia.